Dr. Geoffrey Gibney, MD

• Hematology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Boston University Medical Center-internal Medicine

  Residency Hospital, 2013

• Yale University/yale Cancer Center-hematology/medical Oncology

  Fellowship Hospital, 2011

• University Of Connecticut School Of Medicine

  Medical School, 2005

• Bs, Tufts University, 2000-biochemistry

  Undergraduate School, 2000

• Paradoxical oncogenesis and the long term consequences of BRAF inhibition in melanoma, 2013-05-28

• XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation, 2015-06-03

• Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection, 2019-12-17

• Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions, 2022-03-15

• NRASmutant melanoma: biological behavior and future strategies for therapeutic management, 2012-10-15

• Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin inBRAFwild-type melanoma, 2014-02-21

• Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma, 2019-03-20

• Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting, 2015-05-20

• Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy, 2022-01-12

• Resistance mechanisms to genetic suppression of mutantNRASin melanoma, 2017-09-13

• Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series, 2018-10-11

• Ligand independent EphA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype, 2014-12-26

• The State of Melanoma: Emergent Challenges and Opportunities, 2021-01-07

• Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies, 2017-10-12

• Fibronectin induction abrogates the BRAF inhibitor response ofBRAFV600E/PTEN-null melanoma cells, 2015-06-15

• Conjunctival Melanomas Harbor BRAF and NRAS Mutations-Letter, 2013-10-28

• Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks inBRAFandNRASmutant melanoma, 2014-12-17

• Amuvatinib has cytotoxic effects againstNRAS- but notBRAF-mutant melanoma, 2015-03-30

• Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma, 2014-09-01

• An unholy alliance: co-operation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance, 2013-02-05